Xbrane Biopharma AB 2024 IR
The report highlights Xbrane Biopharma's progress in 2024, including a 225 percent volume increase in Ximluci® sales and its launch in 21 countries. The company secured key global partnerships with Valorum Biologics for US commercialization and Intas Pharmaceuticals for the development of its Nivolumab biosimilar candidate, Xdivane™. Xbrane also resubmitted its Biologics License Application for Ximluci® to the FDA in December 2024. On the sustainability front, Xbrane was awarded the EcoVadis Silver Medal, maintained its Great Place to Work® certification for the fourth consecutive year, and was listed on Allbright's Green List of equal companies.
Company: Xbrane Biopharma AB
Sector: Health Care
Country: Sweden
Year: 2024
Type: IR
Pages: 80
Xbrane Biopharma AB
Annual And Sustainability Report
The report highlights Xbrane Biopharma's progress in 2024, including a 225 percent volume increase in Ximluci® sales and its launch in 21 countries. The company secured key global partnerships with Valorum Biologics for US commercialization and Intas Pharmaceuticals for the development of its Nivolumab biosimilar candidate, Xdivane™. Xbrane also resubmitted its Biologics License Application for Ximluci® to the FDA in December 2024. On the sustainability front, Xbrane was awarded the EcoVadis Silver Medal, maintained its Great Place to Work® certification for the fourth consecutive year, and was listed on Allbright's Green List of equal companies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees